Digitizing Clinical Research Processes – The New Frontier
Jennifer Royer, Director, Regulated Industry Marketing, DocuSign
Jenny Lester, MPH, CCRP, Research Manager for the Women’s Cancer Program, Cedars-Sinai Medical Center
Therica Miller MBA, CCRP, Associate Director, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center
One in three people will be diagnosed with cancer in their lifetime, but according to the NIH, only 3-5% of adult cancer patients participate in clinical trials. Advancing therapies in oncology and other disease areas is at the forefront of academic and commercial R&D. But enrollment and site initiation is often hindered by daunting, time consuming paperwork – from investigator on-boarding to protocols and safety reports.
Researchers at Cedars-Sinai have made great strides in accelerating clinical research by simplifying and digitizing their research enrollment and site initiation processes while adhering to 21 CFR Part 11. Tune in to hear lead researchers at Cedars-Sinai speak about:
• Overcoming challenges in clinical site initiation & maintenance
• Implementing a pilot to test effectiveness of new digital processes
• Identifying and activating use cases ripe for digital investment
• Driving adoption and change management
• Measuring assessing results
• Adhering to compliance standards
About the Sponsors
DocuSign® is changing how business gets done by empowering more than 300,000 companies and 200 million users in 188 countries to sign, send and manage documents anytime, anywhere, on any device, with confidence.
DocuSign replaces printing, faxing, scanning and overnighting documents with the easiest, fastest, most trusted way to make every approval and decision digital.
Organizations of all sizes and industries are accelerating contracts, approvals and workflows with DocuSign’s Digital Transaction Management (DTM) platform and eSignature solution. DocuSign keeps life and business moving forward.For more information please visit www.docusign.com/.